Theragnostics in Austria

Preview this chapter:

Theragnostics in Austria, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9781681088655/chapter-18-1.gif

Over the past decades, Professor Kalevi Kairemo has been a well-known anddear colleague with whom we have excellently cooperated, especially via theinternational organisations IAEA (International Atomic Energy Agency) and TheWARMTH (World Association of Radiopharmaceutical and Molecular Therapy). Thework resulted in the construction of radiotracers using different modal systems,including a variety of radiolabelled peptide analogues such as somatostatin,cholecystokinin (CCK-2/gastrin), or prostate-specific membrane antigen (PSMA)ligand for specific tumour targeting. Radiopharmaceuticals are produced at clinicalgrade in dedicated laboratories for use in SPECT/CT or PET/CT studies. Patientsevaluated by SPECT/CT dosimetry studies are treated with high dose thera(g)nostics.Radioiodine ablation therapy of thyroid cancer remnants, peptide receptor radionuclidetherapy (PRRT) of NET patients, and peptide ligand radionuclide therapy (PLRT) ofPC patients are today the most important therapeutic tools.